Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Volkmann

Showing results (151-160 of 198) with videos related to

Pageof 20
Sort By:
Annals of the Rheumatic Diseases|December 3, 2014
Relationship between quantitative radiographic assessments of interstitial lung disease and physiological and clinical features of systemic sclerosisDonald P Tashkin, Elizabeth R Volkmann, Chi-Hong Tseng, et al.
The Lancet. Rheumatology|September 25, 2023
Sex differences in clinical outcomes and biological profiles in systemic sclerosis-associated interstitial lung disease: a post-hoc analysis of two randomised controlled trialsElizabeth R Volkmann, Donald P Tashkin, Richard Silver, et al.
The Journal of Rheumatology|February 1, 2026
Factor analysis to determine subgroups of systemic sclerosis gastrointestinal symptomsLaura Ross, Dylan Hansen, Susanna Proudman, et al.
Rheumatology (Oxford, England)|February 12, 2022
Dyspnoea and cough in patients with systemic sclerosis-associated interstitial lung disease in the SENSCIS trialElizabeth R Volkmann, Michael Kreuter, Anna M Hoffmann-Vold, et al.
Arthritis Research & Therapy|January 1, 2017
Changes in plasma CXCL4 levels are associated with improvements in lung function in patients receiving immunosuppressive therapy for systemic sclerosis-related interstitial lung diseaseElizabeth R Volkmann, Donald P Tashkin, Michael D Roth, et al.
American Journal of Respiratory and Critical Care Medicine|November 4, 2017
Reliability and minimal clinically important differences of forced vital capacity: Results from the Scleroderma Lung Studies (SLS-I and SLS-II)Suzanne Kafaja, Philip J Clements, Holly Wilhalme, et al.
Thorax|April 10, 2025
Impact of quantitative radiological features of interstitial lung disease on immunomodulatory treatment response in three autoimmune interstitial lung disease cohortsScott M Matson, Grace Hyun J Kim, Stephen M Humphries, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|April 5, 2017
Mycophenolate Mofetil Versus Placebo for Systemic Sclerosis-Related Interstitial Lung Disease: An Analysis of Scleroderma Lung Studies I and IIElizabeth R Volkmann, Donald P Tashkin, Ning Li, et al.
RMD Open|February 16, 2023
Effect of nintedanib in patients with systemic sclerosis-associated interstitial lung disease and risk factors for rapid progressionDinesh Khanna, Toby M Maher, Elizabeth R Volkmann, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|April 15, 2014
Improved transplant-free survival in patients with systemic sclerosis-associated pulmonary hypertension and interstitial lung diseaseElizabeth R Volkmann, Rajeev Saggar, Dinesh Khanna, et al.
Pageof 20

Showing results (151-160 of 198) with videos related to

Sort By:
Pageof 20
Annals of the Rheumatic Diseases|December 3, 2014
Relationship between quantitative radiographic assessments of interstitial lung disease and physiological and clinical features of systemic sclerosisDonald P Tashkin, Elizabeth R Volkmann, Chi-Hong Tseng, et al.
The Lancet. Rheumatology|September 25, 2023
Sex differences in clinical outcomes and biological profiles in systemic sclerosis-associated interstitial lung disease: a post-hoc analysis of two randomised controlled trialsElizabeth R Volkmann, Donald P Tashkin, Richard Silver, et al.
The Journal of Rheumatology|February 1, 2026
Factor analysis to determine subgroups of systemic sclerosis gastrointestinal symptomsLaura Ross, Dylan Hansen, Susanna Proudman, et al.
Rheumatology (Oxford, England)|February 12, 2022
Dyspnoea and cough in patients with systemic sclerosis-associated interstitial lung disease in the SENSCIS trialElizabeth R Volkmann, Michael Kreuter, Anna M Hoffmann-Vold, et al.
Arthritis Research & Therapy|January 1, 2017
Changes in plasma CXCL4 levels are associated with improvements in lung function in patients receiving immunosuppressive therapy for systemic sclerosis-related interstitial lung diseaseElizabeth R Volkmann, Donald P Tashkin, Michael D Roth, et al.
American Journal of Respiratory and Critical Care Medicine|November 4, 2017
Reliability and minimal clinically important differences of forced vital capacity: Results from the Scleroderma Lung Studies (SLS-I and SLS-II)Suzanne Kafaja, Philip J Clements, Holly Wilhalme, et al.
Thorax|April 10, 2025
Impact of quantitative radiological features of interstitial lung disease on immunomodulatory treatment response in three autoimmune interstitial lung disease cohortsScott M Matson, Grace Hyun J Kim, Stephen M Humphries, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|April 5, 2017
Mycophenolate Mofetil Versus Placebo for Systemic Sclerosis-Related Interstitial Lung Disease: An Analysis of Scleroderma Lung Studies I and IIElizabeth R Volkmann, Donald P Tashkin, Ning Li, et al.
RMD Open|February 16, 2023
Effect of nintedanib in patients with systemic sclerosis-associated interstitial lung disease and risk factors for rapid progressionDinesh Khanna, Toby M Maher, Elizabeth R Volkmann, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|April 15, 2014
Improved transplant-free survival in patients with systemic sclerosis-associated pulmonary hypertension and interstitial lung diseaseElizabeth R Volkmann, Rajeev Saggar, Dinesh Khanna, et al.
Pageof 20